<DOC>
<DOCNO>EP-0638317</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Pharmaceutical composition comprising glucosidase- and/or amylaseinhibitors, and a lipase inhibiting agent
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K31365	A61K4500	A61P4300	A61K31365	A61K317034	C07H1500	C07D30512	A61K31715	C07H15203	C07D30500	A61K31715	A61K3170	A61P304	A61K3170	A61K317028	A61K31337	A61P4300	A61K317028	A61P300	A61K4506	A61K4500	A61K31337	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	A61P	A61K	A61K	C07H	C07D	A61K	C07H	C07D	A61K	A61K	A61P	A61K	A61K	A61K	A61P	A61K	A61P	A61K	A61K	A61K	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	A61K45	A61P43	A61K31	A61K31	C07H15	C07D305	A61K31	C07H15	C07D305	A61K31	A61K31	A61P3	A61K31	A61K31	A61K31	A61P43	A61K31	A61P3	A61K45	A61K45	A61K31	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Pharmaceutical composition containing as active ingredient a glucosidase and/or amylase inhibitor and a lipase inhibitor and conventional pharmaceutical vehicles.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
HOFFMANN LA ROCHE
</APPLICANT-NAME>
<APPLICANT-NAME>
F. HOFFMANN-LA ROCHE AG
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
BREMER KLAUS-DIETER
</INVENTOR-NAME>
<INVENTOR-NAME>
SAWLEWICZ PAVEL
</INVENTOR-NAME>
<INVENTOR-NAME>
BREMER, KLAUS-DIETER
</INVENTOR-NAME>
<INVENTOR-NAME>
SAWLEWICZ, PAVEL
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
A pharmaceutical preparation containing a glucosidase and/or amylase
inhibitor and a lipase inhibitor as the active substances and usual pharmaceutical carriers.
A preparation according to claim 1, wherein the glucosidase and/or amylase
inhibitor is acarbose, adiposine, voglibose (AO-128), miglitol (Bay-m-1099), emiglitate (Bay-o-1248),

MDL-25637, camiglibose (MDL-73945), tendamistate, AI-3688, trestatin,
pradimicin-Q or salbostatin.
A preparation according to claim 1, wherein the lipase inhibitor is
tetrahydrolipstatin, lipstatin, FL-386, WAY-121898, Bay-N-3176, valilactone, esterastin,

ebelactone A, ebelactone B or RHC 80267.
A preparation according to claim 1, 2 or 3 containing acarbose and
tetrahydrolipstatin as the active substances.
A product containing a glucosidase and/or amylase inhibitor and a lipase
inhibitor as a combination preparation for the simultaneous, separate or chronologically

spaced use in the treatment of obesity.
A product according to claim 5 containing a glucosidase and/or amylase
inhibitor set forth in claim 2 and a lipase inhibitor set forth in claim 3, especially acarbose and

tetrahydrolipstatin.
The use of a glucosidase and/or amylase inhibitor in combination with a lipase
inhibitor for the production of a pharmaceutical preparation for the treatment of obesity.
The use of acarbose in combination with tetrahydrolipstatin in accordance

with claim 7.
</CLAIMS>
</TEXT>
</DOC>
